BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/27/2022 2:48:53 AM | Browse: 300 | Download: 360
 |
Received |
|
2022-02-14 16:37 |
|
Peer-Review Started |
|
2022-02-14 16:40 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-05 20:05 |
|
Revised |
|
2022-04-13 20:22 |
|
Second Decision |
|
2022-06-22 09:14 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-06-26 06:35 |
|
Articles in Press |
|
2022-06-26 06:35 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-07-14 06:33 |
|
Publish the Manuscript Online |
|
2022-07-27 02:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ângelo Z Mattos, Jose D Debes, Arndt Vogel, Marco Arrese, Xavier Revelo, Tales Henrique S Pase, Muriel Manica and Angelo A Mattos |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| European-Latin American ESCALON Consortium, Funded By The EU Horizon 2020 Program |
825510 |
| Robert Wood Johnson Foundation, Harold Amos Medical Faculty Development Program to JDD |
|
| University of Minnesota Academic Investment Research Program–AIRP Grant to JDD |
|
| Fondo Nacional de Ciencia y Tecnología de Chilex to MA |
FONDECYT-1191145 |
| Agencia Nacional de Investigación y Desarrollo to MA |
ANID-ACE 210009 |
|
| Corresponding Author |
Ângelo Z Mattos, MD, MSc, PhD, Professor, Graduate Program in Medicine: Hepatology, Federal University of Health Sciences of Porto Alegre, 245 Sarmento Leite St., Porto Alegre 90050-170, Brazil. angmattos@hotmail.com |
| Key Words |
Non-alcoholic fatty liver disease; Hepatocellular carcinoma; Hepatocarcinogenesis; Immunology; Immunotherapy; Tyrosine kinase inhibitors |
| Core Tip |
Non-alcoholic fatty liver disease (NAFLD) is an important cause of hepatocellular carcinoma (HCC). While the treatment of advanced HCC has recently undergone a revolution led by immunotherapy, concerns have been raised that NAFLD-related HCC might not respond well to these new therapies. This review will approach the pathophysiology of NAFLD-related liver cancer, the evidence on traditional systemic treatments and the most recent data on immunotherapy for this particular group of patients, showing that the management of this condition should be individualized. |
| Publish Date |
2022-07-27 02:48 |
| Citation |
Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? World J Gastroenterol 2022; 28(28): 3595-3607 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i28/3595.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i28.3595 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
